DDAH2 and cancer: Despite enhanced DDAH2 expression being linked to a handful of cancers such as lung (166) and prostate (184), the lack of a robust and reproducible in vitro DDAH2 activity assay represents a significant limitation for the development and pharmacokinetic characterization of DDAH2 activity modulators.